SI1928879T1 - Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji - Google Patents

Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji

Info

Publication number: SI1928879T1
Authority: SI; Slovenia
Prior art keywords: gold; heterocyclic compounds; kinase modulators; modulators; kinase
Prior art date: 2005-09-22

Application number

SI200631578T

Other languages

English (en)

Inventor

Wayne Vaccaro

Zhong Chen

Dharmpal S. Dodd

Tram N. Huynh

James Lin

Chunjian Liu

Christopher P. Mussari

John S. Tokarski

David R. Tortolani

Stephen T. Wrobleski

Original Assignee

Bristol-Myers Sqiubb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2006-09-22

Publication date

2013-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37716206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1928879(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-22 Application filed by Bristol-Myers Sqiubb Company filed Critical Bristol-Myers Sqiubb Company

2013-06-28 Publication of SI1928879T1 publication Critical patent/SI1928879T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Immunology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Virology (AREA)

SI200631578T 2005-09-22 2006-09-22 Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji SI1928879T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US71951905P	2005-09-22	2005-09-22
US11/524,996 US20070078136A1 (en)	2005-09-22	2006-09-21	Fused heterocyclic compounds useful as kinase modulators
EP06825074A EP1928879B1 (en)	2005-09-22	2006-09-22	Fused heterocyclic compounds useful as kinase modulators
PCT/US2006/037056 WO2007038314A2 (en)	2005-09-22	2006-09-22	Fused heterocyclic compounds useful as kinase modulators

Publications (1)

Publication Number	Publication Date
SI1928879T1 true SI1928879T1 (sl)	2013-06-28

Family

ID=37716206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200631578T SI1928879T1 (sl)	2005-09-22	2006-09-22	Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji

Country Status (24)

Country	Link
US (1)	US20070078136A1 (sl)
EP (1)	EP1928879B1 (sl)
JP (1)	JP5241498B2 (sl)
KR (2)	KR20140058645A (sl)
AR (1)	AR055177A1 (sl)
AU (1)	AU2006295439B2 (sl)
BR (1)	BRPI0616393B8 (sl)
CA (1)	CA2623369C (sl)
CY (1)	CY1114001T1 (sl)
DK (1)	DK1928879T3 (sl)
EA (1)	EA017632B1 (sl)
ES (1)	ES2402664T3 (sl)
GE (1)	GEP20104943B (sl)
HR (1)	HRP20130155T1 (sl)
IL (1)	IL190280A (sl)
NO (1)	NO20081231L (sl)
NZ (1)	NZ566663A (sl)
PE (1)	PE20070520A1 (sl)
PH (1)	PH12013501329B1 (sl)
PL (1)	PL1928879T3 (sl)
PT (1)	PT1928879E (sl)
SI (1)	SI1928879T1 (sl)
TW (2)	TWI478925B (sl)
WO (1)	WO2007038314A2 (sl)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR062207A1 (es)	2006-08-04	2008-10-22	Takeda Pharmaceutical	Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
EP2125819B1 (en) *	2007-03-21	2014-10-22	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
AR067326A1 (es) *	2007-05-11	2009-10-07	Novartis Ag	Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
CA2694261A1 (en) *	2007-07-26	2009-01-29	Novartis Ag	Organic compounds
EP2222639A1 (en) *	2007-11-21	2010-09-01	Decode Genetics EHF	Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
WO2009067604A1 (en) *	2007-11-21	2009-05-28	Decode Genetics Ehf	Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
JP5693239B2 (ja) *	2008-01-23	2015-04-01	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	４−ピリジノン化合物および癌についてのその使用
WO2009100375A1 (en) *	2008-02-06	2009-08-13	Bristol-Myers Squibb Company	Substituted imidazopyridazines useful as kinase inhibitors
UY31676A1 (es)	2008-02-28	2009-09-30		"derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
AU2009226024B2 (en) *	2008-03-20	2012-07-12	Amgen Inc.	Aurora kinase modulators and method of use
BRPI0912668A2 (pt) *	2008-05-13	2016-01-26	Irm Llc	composto e composições como inibidores de quinase
WO2010036407A2 (en) *	2008-05-15	2010-04-01	Biocryst Pharmaceuticals, Inc.	Antiviral nucleoside analogs
NZ602791A (en) *	2008-05-21	2014-04-30	Incyte Corp	Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
JP2011529073A (ja) *	2008-07-24	2011-12-01	ブリストル−マイヤーズスクイブカンパニー	キナーゼ調節因子として有用な縮合ヘテロ環化合物
UY32049A (es) *	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
WO2010027114A1 (en) *	2008-09-05	2010-03-11	Choongwae Pharma Corporation	Use of pyrazole-pyridine derivatives and its salts for treating or reventin osteoporosis
EP2350075B1 (en)	2008-09-22	2014-03-05	Array Biopharma, Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
TWI491610B (zh)	2008-10-09	2015-07-11	必治妥美雅史谷比公司	作為激酶抑制劑之咪唑并嗒腈
KR101853026B1 (ko)	2008-10-22	2018-04-27	어레이 바이오파마 인크.	ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５ａ］ 피리미딘 화합물
WO2010068810A2 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
PA8854101A1 (es) *	2008-12-18	2010-07-27	Ortho Mcneil Janssen Pharm	Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
SG171815A1 (en)	2008-12-19	2011-07-28	Bristol Myers Squibb Co	Carbazole carboxamide compounds useful as kinase inhibitors
WO2010074284A1 (ja)	2008-12-26	2010-07-01	味の素株式会社	ピラゾロピリミジン化合物
AU2010211109B2 (en)	2009-02-06	2014-11-27	Cellzome Limited	Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh)	2009-02-19	2014-11-21	Janssen Pharmaceuticals Inc	作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
MX2011011753A (es)	2009-05-07	2011-11-29	Janssen Pharmaceuticals Inc	Nuevos derivados sustitutos de indazol y aza-indazol como moduladores de la gamma secretasa.
ES2444777T3 (es)	2009-06-12	2014-02-26	Bristol-Myers Squibb Company	Compuestos de nicotinamida útiles como moduladores de quinasas
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2778517A1 (en)	2009-07-15	2011-01-20	Janssen Pharmaceuticals, Inc.	Substituted triazole and imidazole derivatives as gamma secretase modulators
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
NZ599597A (en) *	2009-10-30	2013-05-31	Janssen Pharmaceutica Nv	IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
JPWO2011078221A1 (ja)	2009-12-24	2013-05-09	味の素株式会社	イミダゾピリダジン化合物
PH12012501381A1 (en)	2010-01-15	2012-10-22	Janssen Pharmaceuticals Inc	Novel substituted bicyclic triazole derivatives as gamma secretase modulators
CA2787714C (en)	2010-01-22	2019-04-09	Joaquin Pastor Fernandez	Inhibitors of pi3 kinase
AR080754A1 (es)	2010-03-09	2012-05-09	Janssen Pharmaceutica Nv	Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2563792B1 (en)	2010-04-28	2014-08-27	Bristol-Myers Squibb Company	Imidazopyridazinyl compounds and their uses for cancer
US20130131057A1 (en)	2010-05-13	2013-05-23	Centro Nacional De Investigaciones Oncologicas (Cnio	New bicyclic compounds as pi3-k and mtor inhibitors
CN105693720B (zh)	2010-05-20	2019-01-18	阵列生物制药公司	作为trk激酶抑制剂的大环化合物
EP2582668B1 (en)	2010-06-16	2016-01-13	Bristol-Myers Squibb Company	Carboline carboxamide compounds useful as kinase inhibitors
CA2806655A1 (en)	2010-07-28	2012-02-02	Bayer Intellectual Property Gmbh	Substituted imidazo[1,2-b]pyridazines
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
TWI541243B (zh) *	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
JP2013542259A (ja)	2010-11-12	2013-11-21	ブリストル−マイヤーズスクイブカンパニー	置換アザインダゾール化合物
CA2821817A1 (en)	2010-12-17	2012-06-21	Bayer Intellectual Property Gmbh	Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103370322B (zh)	2010-12-17	2016-02-10	拜耳知识产权有限责任公司	在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
US20130303532A1 (en)	2010-12-17	2013-11-14	Bayer Intellectual Property Gmbh	Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
MX2013010970A (es)	2011-03-24	2013-10-17	Cellzome Ltd	Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
GB201108003D0 (en)	2011-05-13	2011-06-29	Materialise Dental Nv	Endodontic treatment simulation system
WO2012156367A1 (en)	2011-05-17	2012-11-22	Bayer Intellectual Property Gmbh	Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
CN103717604B (zh)	2011-06-01	2016-06-01	拜耳知识产权有限责任公司	取代的氨基咪唑并哒嗪
CN103764656A (zh) *	2011-06-22	2014-04-30	拜耳知识产权有限责任公司	杂环基氨基咪唑并哒嗪
WO2013000924A1 (en)	2011-06-27	2013-01-03	Janssen Pharmaceutica Nv	1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EA023045B1 (ru)	2011-07-15	2016-04-29	Янссен Фармасьютикалз, Инк.	Новые замещенные производные индола в качестве модуляторов гамма-секретазы
WO2013012915A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
CN103814029B (zh)	2011-09-23	2016-10-12	拜耳知识产权有限责任公司	取代的咪唑并哒嗪
WO2013049263A1 (en)	2011-09-27	2013-04-04	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
RU2662443C2 (ru)	2011-11-01	2018-07-26	Ф. Хоффманн-Ля Рош Аг	Имидазопиридазины
WO2013104573A1 (en)	2012-01-10	2013-07-18	F. Hoffmann-La Roche Ag	Pyridazine amide compounds and their use as syk inhibitors
EP2822559B1 (en) *	2012-03-09	2018-05-02	Lexicon Pharmaceuticals, Inc.	Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
EP2825540B1 (en)	2012-03-14	2016-09-14	Bayer Intellectual Property GmbH	Substituted imidazopyridazines
MX355164B (es)	2012-05-16	2018-04-06	Janssen Pharmaceuticals Inc	Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
WO2014001314A1 (en)	2012-06-26	2014-01-03	Janssen Pharmaceutica Nv	Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en)	2012-07-09	2017-03-30	Janssen Pharmaceutica Nv	Inhibitors of phosphodiesterase 10 enzyme
TW201414737A (zh)	2012-07-13	2014-04-16	必治妥美雅史谷比公司	作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer
US9428511B2 (en)	2012-09-06	2016-08-30	Bristol-Myers Squibb Company	Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
AU2013344716B2 (en)	2012-11-16	2018-03-01	University Health Network	Pyrazolopyrimidine compounds
ES2608356T3 (es)	2012-12-20	2017-04-10	Janssen Pharmaceutica Nv	Novedosos derivados tricíclicos de 3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona como moduladores de la secretasa gamma
WO2014100533A1 (en) *	2012-12-21	2014-06-26	Bristol-Myers Squibb Company	NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
JP6283688B2 (ja)	2012-12-21	2018-02-21	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
AU2014206834B2 (en)	2013-01-17	2017-06-22	Janssen Pharmaceutica Nv	Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US9586958B2 (en)	2013-06-11	2017-03-07	Bayer Pharma Aktiengesellschaft	Prodrug derivatives of substituted triazolopyridines
WO2014200885A1 (en)	2013-06-11	2014-12-18	Janssen Pharmaceutica Nv	PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
US9193736B2 (en)	2013-06-11	2015-11-24	Janssen Pharmaceutica, Nv	PDE 10a inhibitors for the treatment of type II diabetes
AR096721A1 (es)	2013-06-25	2016-01-27	Bristol Myers Squibb Co	Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
BR112015031432A2 (pt)	2013-06-25	2017-07-25	Bristol Myers Squibb Co	compostos de carbazol carboxamida úteis como inibidores de cinase
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
AR097543A1 (es) *	2013-09-06	2016-03-23	Lexicon Pharmaceuticals Inc	COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
ES2702126T3 (es) *	2013-12-10	2019-02-27	Bristol Myers Squibb Co	Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2015097121A1 (en)	2013-12-23	2015-07-02	Norgine B.V.	Compounds useful as ccr9 modulators
US10562897B2 (en)	2014-01-16	2020-02-18	Janssen Pharmaceutica Nv	Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
TW201613927A (en)	2014-09-01	2016-04-16	Bayer Pharma AG	Method for preparation of substituted imidazopyridazines
CN110511209B (zh)	2014-10-24	2022-07-05	百时美施贵宝公司	可用作激酶抑制剂的吲哚甲酰胺化合物
TWI746426B (zh)	2014-11-16	2021-11-21	美商亞雷生物製藥股份有限公司	(S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
KR101635173B1 (ko)	2014-12-03	2016-06-30	충남직물공업협동조합	디지털프린팅 날염 친환경 자카드직물의 제조방법 및 그 직물
CN107108633B (zh)	2014-12-19	2020-05-12	詹森药业有限公司	作为PI3Kβ抑制剂的杂环基连接的咪唑并哒嗪衍生物
BR112017012930A2 (pt)	2014-12-19	2018-01-09	Janssen Pharmaceutica Nv	derivados de imidazopiridazina como inibidores de pi3kbeta.
CA2978170C (en)	2015-03-09	2024-02-27	Aurigene Discovery Technologies Limited	Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
WO2017070089A1 (en)	2015-10-19	2017-04-27	Incyte Corporation	Heterocyclic compounds as immunomodulators
TN2018000138A1 (en)	2015-10-26	2019-10-04	Array Biopharma Inc	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
DK3377488T3 (da)	2015-11-19	2022-10-03	Incyte Corp	Heterocykliske forbindelser som immunomodulatorer
MY199705A (en)	2015-12-22	2023-11-20	Incyte Corp	Heterocyclic compounds as immunomodulators
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
HUE068971T2 (hu)	2016-04-04	2025-02-28	Loxo Oncology Inc	(S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
TW201808950A (zh)	2016-05-06	2018-03-16	英塞特公司	作為免疫調節劑之雜環化合物
SI3458456T1 (sl)	2016-05-18	2021-04-30	Loxo Oncology, Inc.	Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US20170342060A1 (en)	2016-05-26	2017-11-30	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2017210399A1 (en) *	2016-06-02	2017-12-07	Celgene Corporation	Animal and human anti-malarial agents
SG11201811414TA (en)	2016-06-20	2019-01-30	Incyte Corp	Heterocyclic compounds as immunomodulators
EP3484866B1 (en)	2016-07-14	2022-09-07	Incyte Corporation	Heterocyclic compounds as immunomodulators
MA46045A (fr)	2016-08-29	2021-04-28	Incyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
ES2849974T3 (es) *	2016-11-17	2021-08-24	Bristol Myers Squibb Co	Moduladores de imidazopiridazina de IL-12, IL-23 y/o IFNalfa
WO2018109667A1 (en)	2016-12-15	2018-06-21	Nestec Sa	Compositions and methods that modulate white blood cells or neutrophils in a companion animal
WO2018119266A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Benzooxazole derivatives as immunomodulators
WO2018119236A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119221A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Pyridine derivatives as immunomodulators
US20180179202A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
RU2770363C2 (ru)	2017-04-05	2022-04-15	Куровир Аб	Гетероароматические соединения, пригодные в терапии
CA3059939A1 (en) *	2017-04-21	2018-10-25	Kyn Therapeutics	Indole ahr inhibitors and uses thereof
US11046698B2 (en) *	2017-07-28	2021-06-29	Nimbus Lakshmi, Inc.	TYK2 inhibitors and uses thereof
WO2019169249A1 (en) *	2018-03-01	2019-09-06	The Johns Hopkins University	INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
FI3774791T3 (fi)	2018-03-30	2023-03-21	Incyte Corp	Heterosyklisiä yhdisteitä immunomodulaattoreina
BR112020022936A2 (pt)	2018-05-11	2021-02-02	Incyte Corporation	derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
KR102813547B1 (ko)	2018-07-27	2025-05-27	코크리스탈 파마, 아이엔씨.	인플루엔자바이러스 복제 억제제로서의 피롤로[2,3-b]피리딘 유도체
CA3126034A1 (en) *	2019-01-23	2020-07-30	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
EP3935058B1 (en) *	2019-03-05	2024-08-21	Bristol-Myers Squibb Company	Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CA3139161A1 (en) *	2019-05-17	2020-11-26	Kinnate Biopharma Inc.	Inhibitors of fibroblast growth factor receptor kinases
US11753406B2 (en)	2019-08-09	2023-09-12	Incyte Corporation	Salts of a PD-1/PD-L1 inhibitor
MX2022003578A (es)	2019-09-30	2022-05-30	Incyte Corp	Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
BR112022009031A2 (pt)	2019-11-11	2022-10-11	Incyte Corp	Sais e formas cristalinas de um inibidor de pd-1/pd-l1
CN116057045A (zh)	2020-06-05	2023-05-02	金耐特生物制药公司	成纤维细胞生长因子受体激酶抑制剂
TW202233615A (zh)	2020-11-06	2022-09-01	美商英塞特公司	Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US11780836B2 (en)	2020-11-06	2023-10-10	Incyte Corporation	Process of preparing a PD-1/PD-L1 inhibitor
MX2023005362A (es)	2020-11-06	2023-06-22	Incyte Corp	Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
CN117355533A (zh) *	2021-06-22	2024-01-05	株式会社Lg化学	作为蛋白激酶抑制剂的新型化合物
EP4268824A1 (en) *	2022-04-26	2023-11-01	Manros Therapeutics	Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament
WO2025199359A1 (en) *	2024-03-21	2025-09-25	The Translational Genomics Research Institute	Methods of modulating cdk7 and flt3 using fused bicyclic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166851A (en)	1977-05-16	1979-09-04	Merck & Co., Inc.	Certain imidazo(1,2a)pyridine derivatives
CH635587A5 (fr) *	1978-01-09	1983-04-15	Aron Sa	Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
FR2619818B1 (fr) *	1987-09-01	1990-01-12	Sanofi Sa	Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5260285A (en)	1990-12-07	1993-11-09	Merck & Co., Inc.	Substituted imidazopyridazines as angiotensin II antagonists
DE4327027A1 (de)	1993-02-15	1994-08-18	Bayer Ag	Imidazoazine
CZ68199A3 (cs)	1996-08-28	1999-11-17	Pfizer Inc.	6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
CA2432417A1 (fr) *	2000-12-20	2002-06-27	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.)	Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2850653A1 (fr) *	2003-02-04	2004-08-06	Univ Pasteur	Derives de pyrazolotriazine, procede de preparation et utilisations
MXPA05008955A (es) *	2003-02-28	2006-02-22	Teijin Pharma Ltd	Derivados de pirazolo [1,5-a] pirimidina.
DE10356579A1 (de) *	2003-12-04	2005-07-07	Merck Patent Gmbh	Aminderivate
TW200536536A (en) *	2004-02-25	2005-11-16	Schering Corp	Pyrazolotriazines as kinase inhibitors
US7537840B2 (en) *	2004-08-05	2009-05-26	H.B. Licensing & Financing, Inc.	Polyamide adhesive and articles including the same
US7557103B2 (en)	2005-04-05	2009-07-07	Eli Lilly And Company	Imidazopyridazine compounds

2006
- 2006-09-21 US US11/524,996 patent/US20070078136A1/en not_active Abandoned
- 2006-09-22 SI SI200631578T patent/SI1928879T1/sl unknown
- 2006-09-22 PT PT68250745T patent/PT1928879E/pt unknown
- 2006-09-22 PE PE2006001149A patent/PE20070520A1/es active IP Right Grant
- 2006-09-22 AU AU2006295439A patent/AU2006295439B2/en not_active Ceased
- 2006-09-22 EA EA200800873A patent/EA017632B1/ru not_active IP Right Cessation
- 2006-09-22 NZ NZ566663A patent/NZ566663A/en not_active IP Right Cessation
- 2006-09-22 KR KR1020147007661A patent/KR20140058645A/ko not_active Withdrawn
- 2006-09-22 GE GEAP200610649A patent/GEP20104943B/en unknown
- 2006-09-22 DK DK06825074.5T patent/DK1928879T3/da active
- 2006-09-22 HR HRP20130155TT patent/HRP20130155T1/hr unknown
- 2006-09-22 BR BRPI0616393A patent/BRPI0616393B8/pt not_active IP Right Cessation
- 2006-09-22 ES ES06825074T patent/ES2402664T3/es active Active
- 2006-09-22 KR KR1020087009516A patent/KR101399766B1/ko not_active Expired - Fee Related
- 2006-09-22 TW TW102124973A patent/TWI478925B/zh not_active IP Right Cessation
- 2006-09-22 PL PL06825074T patent/PL1928879T3/pl unknown
- 2006-09-22 WO PCT/US2006/037056 patent/WO2007038314A2/en not_active Ceased
- 2006-09-22 CA CA2623369A patent/CA2623369C/en active Active
- 2006-09-22 JP JP2008532430A patent/JP5241498B2/ja not_active Expired - Fee Related
- 2006-09-22 TW TW095135141A patent/TWI441825B/zh not_active IP Right Cessation
- 2006-09-22 EP EP06825074A patent/EP1928879B1/en active Active
- 2006-09-25 AR ARP060104153A patent/AR055177A1/es active IP Right Grant
2008
- 2008-03-10 NO NO20081231A patent/NO20081231L/no not_active Application Discontinuation
- 2008-03-18 IL IL190280A patent/IL190280A/en active IP Right Grant
2013
- 2013-05-09 CY CY20131100374T patent/CY1114001T1/el unknown
- 2013-06-21 PH PH12013501329A patent/PH12013501329B1/en unknown

Also Published As

Publication number	Publication date
KR101399766B1 (ko)	2014-06-18
JP5241498B2 (ja)	2013-07-17
WO2007038314A2 (en)	2007-04-05
TWI441825B (zh)	2014-06-21
ES2402664T3 (es)	2013-05-07
PH12013501329B1 (en)	2019-11-08
CA2623369A1 (en)	2007-04-05
BRPI0616393B8 (pt)	2021-05-25
PE20070520A1 (es)	2007-08-29
AU2006295439B2 (en)	2012-09-13
DK1928879T3 (da)	2013-05-21
CA2623369C (en)	2014-11-18
US20070078136A1 (en)	2007-04-05
EA200800873A1 (ru)	2008-08-29
BRPI0616393A2 (pt)	2011-06-21
EA017632B1 (ru)	2013-02-28
PL1928879T3 (pl)	2013-07-31
PH12013501329A1 (en)	2014-08-27
HRP20130155T1 (hr)	2013-03-31
WO2007038314A3 (en)	2007-07-12
TW200804385A (en)	2008-01-16
TW201350488A (zh)	2013-12-16
BRPI0616393B1 (pt)	2020-03-24
IL190280A (en)	2013-08-29
CY1114001T1 (el)	2016-07-27
KR20140058645A (ko)	2014-05-14
EP1928879B1 (en)	2013-02-13
KR20080063344A (ko)	2008-07-03
NZ566663A (en)	2011-03-31
PT1928879E (pt)	2013-04-15
TWI478925B (zh)	2015-04-01
EP1928879A2 (en)	2008-06-11
IL190280A0 (en)	2009-09-22
AR055177A1 (es)	2007-08-08
AU2006295439A1 (en)	2007-04-05
GEP20104943B (en)	2010-04-12
JP2009509961A (ja)	2009-03-12
NO20081231L (no)	2008-04-16

Publication	Publication Date	Title
SI1928879T1 (sl)	2013-06-28	Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji
SI3090730T1 (sl)	2024-07-31	Tablete, ki vsebujejo eltrombopag olamin
NL1030863A1 (nl)	2006-07-10	Heteroaromatische chinolineverbindingen.
SI3670528T1 (sl)	2022-01-31	Sredstva, ki vežejo sklerostin
BRPI0914772A2 (pt)	2015-10-20	compostos heterocíclicos 1,2-dissubstituídos
NL1031385A1 (nl)	2006-09-20	Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
BRPI0923786A2 (pt)	2016-07-26	compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
ATE499369T1 (de)	2011-03-15	Heterozyklische verbindung
CY2013047I1 (el)	2015-11-04	Ενωσεις διαρυλυδαντοϊνης
EP1873153A4 (en)	2009-09-30	HETEROCYCLIC CONNECTION
NL1033095A1 (nl)	2007-06-26	Littrow-interferometer.
DK2049079T3 (da)	2017-01-02	Sammensætninger, der indeholder kvaternære ammoniumforbindelser
CY2013044I1 (el)	2015-11-04	Δικυκλικες ετεροαρυλ ενωσεις
ATE477257T1 (de)	2010-08-15	Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen
PT1879873E (pt)	2014-01-03	Compostos de azol neuroterapêuticos
DE602006007875D1 (de)	2009-08-27	Kapseln
SI1725218T1 (sl)	2014-09-30	Farmacevtski sestavek, ki obsega pimobendan
DK1860941T3 (da)	2009-03-02	Biphenyl-N-(4-pyridyl)methylsufonamider
ATE512953T1 (de)	2011-07-15	Heterocyclische verbindungen
NL1031335A1 (nl)	2006-09-12	Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
DE602006018341D1 (de)	2010-12-30	Antihypercholesterinämische verbindungen
NL1030382A1 (nl)	2006-05-11	Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen.
DE502006001027D1 (de)	2008-08-14	Cyanuraten
NL1031627A1 (nl)	2006-10-23	Acylaminobicyclische heteroaromatische verbindingen en toepassingen daarvan.
EP1853274A4 (en)	2010-12-15	2-METHYLENE-19-NOR- (20S-24S) - 1ALPHA, 25-D HYDROXYVITAMINE-D2